Welcome to our dedicated page for Icici Bank SEC filings (Ticker: IBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ICICI Bank鈥檚 dual identity as one of India鈥檚 largest lenders and a New York鈥搇isted ADR makes its disclosures richer鈥攁nd more intricate鈥攖han most peers. From granular reports on non-performing assets to Basel III capital snapshots, every SEC document here shows how the bank balances rapid digital expansion with disciplined risk control.
Stock Titan captures each release the moment it reaches EDGAR鈥攚hether the annual report 10-K or the latest ICICI Bank quarterly earnings report 10-Q filing鈥攁nd layers on AI-powered summaries that turn dense accounting language into clear, usable insight. Need to follow ICICI Bank insider trading Form 4 transactions, scan an 8-K material events explained alert, or simply have ICICI Bank SEC filings explained simply? Our engine surfaces net interest margin shifts, NPA movements, and executive stock grants in seconds.
- AG真人官方-time alerts for ICICI Bank Form 4 insider transactions real-time
- Concise ICICI Bank earnings report filing analysis every quarter
- Clear views of pay packages inside the ICICI Bank proxy statement executive compensation filings
- Risk-factor context through the ICICI Bank annual report 10-K simplified narrative
By combining complete coverage, instantaneous updates, and expert commentary, we make understanding ICICI Bank SEC documents with AI part of your daily workflow鈥攏o more navigating hundreds of pages alone while tracking ICICI Bank executive stock transactions Form 4.
BellRing Brands, Inc. (BRBR) 鈥� Form 144 filing
Insider Darcy Davenport has notified the SEC of intent to sell 1,600 common shares via Apex Clearing on or after 25 Jul 2025. The block is valued at about $87 k against 128.8 m shares outstanding (鈮�0.01 % of float).
The notice also lists eight prior weekly sales between 30 May 鈥� 18 Jul 2025, each for 1,600 shares, producing aggregate gross proceeds of roughly $0.76 m. Shares were originally received as RSU/PSU awards on 11 Nov 2024.
No operational, earnings or strategic disclosures are included; the form solely satisfies Rule 144 requirements for the proposed disposition.
On July 25 2025, OneMain Holdings, Inc. (NYSE: OMF) filed Form 8-K to furnish two disclosures:
- Item 2.02 鈥� Results of Operations: A press release (Exhibit 99.1) with financial results for the quarter ended June 30 2025 was released; the 8-K itself contains no revenue, EPS or credit quality figures. The information is furnished, not filed, limiting Section 18 liability and preventing automatic incorporation into Securities Act filings.
- Item 7.01 鈥� Regulation FD: The board declared a cash dividend of $1.04 per share, payable August 13 2025 to holders of record on August 4 2025.
No other financial statements, pro-formas or major transactions were provided.
ICICI Bank (NYSE: IBN) posted robust Q1-FY26 standalone results. Total income rose 11.9% YoY to 鈧�51,452 cr, while net profit climbed 15.5% YoY to 鈧�12,768 cr. Net interest income reached 鈧�21,635 cr, up 10.6% YoY; non-interest income (ex-treasury) grew 13.7% to 鈧�7,264 cr. Core operating profit advanced 13.6% YoY to 鈧�17,505 cr.
Margins & asset quality. NIM stood at 4.34% (Q4-FY25: 4.41%). Gross NPA ratio improved to 1.67% (2.15% a year ago); net NPA ratio fell to 0.41%. Provisioning coverage on NPAs is 75.3%. Provisions rose to 鈧�1,815 cr versus 鈧�1,332 cr in Q1-FY25.
Balance-sheet growth. Domestic loans expanded 12.0% YoY to 鈧�13.31 trn; period-end deposits grew 12.8% YoY to 鈧�16.09 trn, with average CASA ratio at 38.7%. Capital adequacy remains strong: total CAR 16.97%, CET-1 16.31% (regulatory minima: 11.70% & 8.20%).
Strategic action. Board approved acquisition of the remaining 100% of ICICI Prudential Pension Funds Management for 鈧�2,035 mn, pending RBI & PFRDA approvals, to enhance 鈥淐ustomer 360鈥� synergies.
Consolidated view. Group PAT rose 15.9% YoY to 鈧�13,558 cr; assets grew 10.9% YoY to 鈧�26.69 trn.
Q1-2026 (quarter ended 30 Jun 2025) snapshot:
- Standalone PAT 鈧�12,768 cr, +15.5% YoY; consolidated PAT 鈧�13,558 cr, +15.9% YoY.
- Net interest income 鈧�21,635 cr, +10.6% YoY; NIM 4.34% vs 4.36% YoY and 4.41% QoQ.
- Operating profit before provisions 鈧�18,746 cr; provisions 鈧�1,815 cr (鈫� YoY) with PCR at 75.3%.
- Total income 鈧�51,452 cr (+11.9% YoY); basic EPS 鈧�17.91 vs 鈧�15.73.
Balance-sheet & risk: Advances 鈧�13.64 trn (+11.5% YoY); domestic loans +12%. Deposits 鈧�16.09 trn (+12.8% YoY); CASA avg. 38.7%. GNPA ratio 1.67% (2.15% YoY); NNPA 0.41%. Capital adequacy 16.97% and CET-1 16.31% (well above norms). Contingency buffer remains 鈧�13,100 cr.
Strategic moves: Board okays cash acquisition of 100% of ICICI Prudential Pension Funds for 鈧�2,035 mn to create pension-led synergies, pending RBI/PFRDA approvals. Bank issued 鈧�1,000 cr Basel-III Tier-2 bonds and allotted 13.6 mn ESOP shares. Auditors delivered unmodified limited-review reports on both standalone and consolidated results.
ASML (ASML) filed a Form 6-K summarizing headline results for Q2 2025 and updated full-year guidance.
- Q2 2025 net sales: 鈧�7.7 billion.
- Q2 2025 net income: 鈧�2.3 billion.
- FY 2025 outlook: total net-sales growth of ~15% with gross margin around 52%.
The filing mainly serves as a cover document; detailed financial statements and the full press release are contained in Exhibits 99.1-99.4.
Biotechnology Value Fund and affiliated entities have filed a Schedule 13G disclosing a collective 7.4% passive stake in Nektar Therapeutics (NASDAQ: NKTR). The filing, dated 9 July 2025 with an event date of 1 July 2025, reports aggregate beneficial ownership of 1,276,595 common shares out of 17,301,061 shares outstanding following the company鈥檚 recent public offering.
The ownership is spread across multiple Delaware and Cayman-based vehicles: Biotechnology Value Fund (LP) holds 661,758 shares (3.8%), Biotechnology Value Fund II (LP) holds 517,813 shares (3.0%), and Biotechnology Value Trading Fund OS (LP) holds 71,367 shares (<1%). Control is exercised jointly through the general partners BVF GP Holdings LLC and BVF Partners L.P., with Mark N. Lampert signing on behalf of each entity. All shares are held with shared voting and dispositive power; none of the reporting persons claims sole authority.
The filing is made on Form 13G鈥攊ndicating a passive investment intent rather than an activist position鈥� and includes the customary certification that the securities were not acquired to influence control of the issuer. No other material transactions, derivatives, or lock-up arrangements are disclosed.
Key take-aways for investors: BVF鈥檚 aggregated 7.4% stake makes it one of the largest outside shareholders of Nektar, signalling confidence from a specialist biotech investor group. However, because the filing is passive, immediate governance or strategic changes should not be expected.
On 30 June 2025, Takeda Pharmaceutical Company Limited (NYSE: TAK) furnished a Form 6-K to the U.S. Securities and Exchange Commission. The filing鈥檚 sole purpose is to transmit Exhibit 99.1鈥攖he company鈥檚 2025 Annual Integrated Report鈥攖o American investors in accordance with Exchange Act Rule 13a-16. No earnings figures, transactional details, or additional disclosures are contained within the body of the Form 6-K itself. The document was executed by Chief Accounting Officer and Corporate Controller Norimasa Takeda.
This routine submission keeps Takeda compliant with U.S. reporting obligations for foreign private issuers and makes its full FY-2025 Integrated Report publicly available. Stakeholders seeking financial statements, strategy discussions, or risk factors must review Exhibit 99.1 directly, as those details are not replicated in the cover filing.
FAQ
What is the current stock price of Icici Bank (IBN)?
What is the market cap of Icici Bank (IBN)?
What are the primary service segments of ICICI Bank Limited?
How does ICICI Bank generate revenue?
What makes ICICI Bank's retail banking segment significant?
How does ICICI Bank ensure regulatory compliance?
What role does technology play at ICICI Bank?
How does ICICI Bank position itself in the competitive banking landscape?
What risk management measures are in place at ICICI Bank?
How does ICICI Bank serve its corporate and institutional clients?
What is the significance of the bank鈥檚 domestic operations?
How does ICICI Bank integrate digital banking into its services?
